

CITATION REPORT

List of articles citing

Pharmacotherapy for erectile dysfunction

DOI: 10.1111/j.1743-6109.2009.01627.x
Journal of Sexual Medicine, 2010, 7, 524-40.

Source: <https://exaly.com/paper-pdf/48091038/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
147	Allergic contact dermatitis caused by apomorphine hydrochloride in a carer. 2010 , 63, 112-5		7
146	Vascular alterations and sexual function in systemic sclerosis. 2010 , 2010, 139020		10
145	Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy: an update. 2010 , 25, 392-396		
144	The future is today: emerging drugs for the treatment of erectile dysfunction. 2010 , 15, 467-80		61
143	An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. 2010 , 7, 603-9		41
142	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. 2010 , 19, 1427-37		61
141	Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. 2011 , 63, 811-59		213
140	Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. 2011 , 1812, 859-66		14
139	Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2297-313	4	12
138	Long-term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model. 2011 , 108, 116-22		14
137	Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. <i>Journal of Sexual Medicine</i> , 2011 , 8, 696-704	1.1	31
136	Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings. <i>Journal of Sexual Medicine</i> , 2011 , 8, 1061-71	1.1	33
135	Role of a novel tetrodotoxin-resistant sodium channel in the nitroergic relaxation of corpus cavernosum from the South American rattlesnake <i>Crotalus durissus terrificus</i> . <i>Journal of Sexual Medicine</i> , 2011 , 8, 1616-25	1.1	10
134	The ability of the general male public to assess their suitability to take 50-mg sildenafil: an assessment of the comprehension of patient information materials via internet survey. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2038-47	1.1	4
133	The natural progression and regression of erectile dysfunction: follow-up results from the MMAS and MALES studies. <i>Journal of Sexual Medicine</i> , 2011 , 8, 1917-24	1.1	10
132	Impact of systemically active neurohumoral factors on the erectile response of the rat. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2461-71	1.1	2
131	A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2617-24	1.1	20

130	Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2894-903	1.1	55
129	New therapeutic targets for the treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2011 , 8, 3271-90	1.1	11
128	Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. <i>Journal of Sexual Medicine</i> , 2011 , 8, 3418-32	1.1	71
127	Development and validation of a GC/MS method for the determination of tadalafil in whole blood. 2011 , 56, 577-81		28
126	Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. <i>European Urology</i> , 2011 , 60, 527-35	10.2	42
125	A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1341-1348	4	11
124	Beneficial effect of vardenafil on aortic stiffness and wave reflections. 2012 , 52, 1215-21		8
123	Dysfonction Érectile : prise en charge diagnostique et thérapeutique. 2012 , 9, 1-11		
122	Molecular and functional characterization of ORAI and STIM in human corporeal smooth muscle cells and effects of the transfer of their dominant-negative mutant genes into diabetic rats. 2012 , 187, 1903-10		8
121	Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis. 2012 , 38, 112-22		4
120	Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. 2012 , 87, 843-52		63
119	Animal models of erectile dysfunction (ED): potential utility of non-human primates as a model of atherosclerosis-induced vascular ED. <i>International Journal of Impotence Research</i> , 2012 , 24, 91-100	2.3	11
118	Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. 2012 , 53, 377-85		8
117	10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. <i>Journal of Sexual Medicine</i> , 2012 , 9, 265-70	1.1	31
116	A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1122-33	1.1	66
115	A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1418-29	1.1	25
114	A case-control analysis on the association between erectile dysfunction and sudden sensorineural hearing loss in Taiwan. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1411-7	1.1	4
113	Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. <i>Journal of Sexual Medicine</i> , 2012 , 9, 2361-9	1.1	77

112	Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms. 2012 , 4 Suppl 1, 75-80		2
111	Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. 2012 , 10, 59		26
110	3D-QSAR of amino-substituted pyrido[3,2B]pyrazinones as PDE-5 inhibitors. 2012 , 21, 202-211		8
109	Low nitric oxide bioavailability is associated with better responses to sildenafil in patients with erectile dysfunction. 2013 , 386, 805-11		15
108	PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. 2013 , 8, 150-159		12
107	Herb-drug interaction of Epimedium sagittatum (Sieb. et Zucc.) maxim extract on the pharmacokinetics of sildenafil in rats. 2013 , 18, 7323-35		15
106	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 130-71	1.1	117
105	Emerging drugs for autonomic dysfunction in Parkinson's disease. 2013 , 18, 39-53		22
104	An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. 2013 , 67, 333-41		36
103	Erectile dysfunction. 2013 , 381, 153-65		545
102	Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. 2013 , 5, 35-41		32
101	Density and distribution of connexin 43 in corpus cavernosum tissue from diabetic and hypogonadal patients with erectile dysfunction. 2013 , 13, 7-12		4
100	Pathophysiological role of the renin-angiotensin system on erectile dysfunction. 2013 , 43, 978-85		30
99	Exploring the association between erectile rigidity and treatment adherence with sildenafil. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1861-6	1.1	5
98	The effect of long-term oral tadalafil treatment on corpus cavernosum function in an experimental spinal cord transection rat model. 2013 , 51, 663-7		4
97	Sexual function in the aging male. 103-115		
96	Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men. 2014 ,		
95	Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. 2014 , 19, 53-64		17

94	Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives. 2014 , 2014, 878670		51
93	Alprostadil for the treatment of impotence. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 421-8	4	38
92	Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors?. 2014 , 2, 96-102		11
91	The role of intraurethral alprostadil as a first-choice erectile dysfunction treatment option in special populations: a proposed treatment algorithm. 2014 , 11, 17-26		2
90	Integrative Approaches to the Treatment of Erectile Dysfunction. 2014 , 6, 114-123		8
89	Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. <i>European Urology</i> , 2014 , 65, 455-64	10.2	29
88	Increased expression of TRPC4 channels associated with erectile dysfunction in diabetes. 2014 , 2, 550-8		8
87	The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. 2014 , 2, 45-50		20
86	Vardenafil dihydrochloride. 2014 , 39, 515-44		7
85	Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. 2014 , 21, 1041-5		75
84	Clinical and molecular genetics of the phosphodiesterases (PDEs). 2014 , 35, 195-233		157
83	Estudio aleatorizado, abierto con comparaci3n cruzada de autoconfianza sexual y otros resultados cl3nicos terap3uticos tras la administraci3n de tadalafil una vez al d3a vs. tadalafil o sildenafil a demanda, en hombres mexicanos con disfunci3n er3ctil. 2014 , 74, 155-164		
82	Intraurethral alprostadil in the management of erectile dysfunction: a reappraisal of the clinical evidence. 2014 , 11, 3-15		1
81	Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. 2015 , 69, 1496-507		11
80	Update on the Treatment of Erectile Dysfunction. 2015 ,		1
79	Endothelial nitric oxide synthase polymorphisms and erectile dysfunction: a meta-analysis. <i>Journal of Sexual Medicine</i> , 2015 , 12, 1319-28	1.1	11
78	Effects of three-times-per-week versus on-demand tadalafil treatment on erectile function and continence recovery following bilateral nerve sparing radical prostatectomy: results of a prospective, randomized, and single-center study. 2015 , 31, 90-5		15
77	Intracavernosal Injection for the Diagnosis, Evaluation, and Treatment of Erectile Dysfunction: A Review. <i>Sexual Medicine Reviews</i> , 2015 , 3, 11-23	5.6	30

76	Emerging drugs for the treatment of erectile dysfunction. 2015 , 20, 263-75		21
75	A convenient formation of aporphine core via benzyne chemistry: conformational analysis and synthesis of (R)-aporphine. 2015 , 56, 6848-6851		15
74	Results from an online survey investigating ED patients' insights and treatment expectations. <i>International Journal of Impotence Research</i> , 2015 , 27, 191-6	2.3	12
73	Total Syntheses of Aporphine Alkaloids via Benzyne Chemistry: An Approach to the Formation of Aporphine Cores. 2015 , 80, 10033-40		32
72	Effect of the novel BKCa channel opener LDD175 on the modulation of corporal smooth muscle tone. <i>Journal of Sexual Medicine</i> , 2015 , 12, 29-38	1.1	9
71	Does it matter how tadalafil improves lower urinary tract symptoms?. <i>European Urology</i> , 2015 , 67, 123-124.2		10
70	Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. <i>International Journal of Impotence Research</i> , 2015 , 27, 33-7	2.3	9
69	An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction. <i>Asian Journal of Andrology</i> , 2016 , 18, 773-9	2.8	10
68	Pharmacology of drugs used for the treatment of erectile dysfunction. 2016 , 48-55		0
67	A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. 2016 , 8, 100-17		8
66	Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors. 2016 , 4, e225-e232		39
65	First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. 2016 , 4, 1002-1009		42
64	Avanafil for the treatment of erectile dysfunction. 2016 , 9, 1163-70		9
63	Penile implant surgery. 2016 , 258-269		
62	The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. 2016 , 15, 141-52		35
61	Adulterated and Counterfeit Male Enhancement Nutraceuticals and Dietary Supplements Pose a Real Threat to the Management of Erectile Dysfunction: A Global Perspective. 2016 , 13, 660-93		13
60	The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. 2016 , 15, 237-47		39
59	[Erectile dysfunction : Current diagnostics and treatment]. 2017 , 56, 519-529		9

58	Chromatographic fingerprinting as a strategy to identify regulated plants in illegal herbal supplements. 2017 , 164, 490-502		26
57	Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men. 2017 ,		78
56	Delivery of intracavernosal therapies using needle-free injection devices. <i>International Journal of Impotence Research</i> , 2017 , 29, 225-228	2.3	5
55	Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: A nationwide cohort study. 2017 , 24, 1498-1505		6
54	Impact on the Quality of Erections after Completing a Low-Intensity Extracorporeal Shock Wave Treatment Cycle on a Group of 710 Patients. 2017 , 2017, 1843687		6
53	Phosphodiesterase type 5 and cancers: progress and challenges. 2017 , 8, 99179-99202		28
52	An update on emerging drugs for the treatment of erectile dysfunction. 2018 , 23, 319-330		9
51	Erectile Dysfunction: Evaluation and Pathophysiology. 2018 , 184-186		
50	Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors. <i>Frontiers in Pharmacology</i> , 2018 , 9, 59	5.6	6
49	Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. A prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. <i>International Journal of Impotence Research</i> , 2019 , 31, 195-203	2.3	24
48	Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis. <i>Translational Andrology and Urology</i> , 2019 , 8, 387-394	2.3	6
47	Carotid artery intima-media thickness can predict the response of patients with erectile dysfunction to phosphodiesterase 5 inhibitors. <i>International Journal of Impotence Research</i> , 2019 , 31, 139-144	2.3	5
46	Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: a comparative randomized prospective study. <i>International Urology and Nephrology</i> , 2019 , 51, 1491-1499	2.3	1
45	Radial shockwave therapy for male erectile rejuvenation in a dermatology and/or medical aesthetic practice. <i>Journal of Cosmetic Dermatology</i> , 2019 , 18, 1596-1600	2.5	2
44	Current diagnosis and management of erectile dysfunction. <i>Medical Journal of Australia</i> , 2019 , 210, 469-476		29
43	Radical prostatectomy and simultaneous penile prosthesis implantation: a narrative review. <i>International Journal of Impotence Research</i> , 2020 , 32, 274-280	2.3	2
42	Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction. <i>International Journal of Impotence Research</i> , 2020 , 32, 345-351	2.3	3
41	Effects of Enzymatic Hydrolysate of Oyster on Erectile Function in Male Hemicastrated Rats. <i>International Journal of Peptide Research and Therapeutics</i> , 2020 , 26, 2001-2007	2.1	1

40	Effect of penile rehabilitation with low intensity extracorporeal shock wave therapy on erectile function recovery following robot-assisted laparoscopic prostatectomy. <i>Translational Andrology and Urology</i> , 2020 , 9, 1559-1565	2.3	2
39	Ionic Channels as Potential Therapeutic Targets for Erectile Dysfunction: A Review. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1120	5.6	1
38	Relaxation Effect of Patchouli Alcohol in Rat Corpus Cavernosus and Its Underlying Mechanisms. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020 , 2020, 3109069	2.3	0
37	Pharmacology and perspectives in erectile dysfunction in man. <i>Pharmacology & Therapeutics</i> , 2020 , 208, 107493	13.9	17
36	Effect of Intracavernosal Injection of Prostaglandin E1 on Duration and Rigidity of Erection in Patients With Vasculogenic Erectile Dysfunction: Is It Dose Dependent?. <i>Urology</i> , 2021 , 148, 173-178	1.6	1
35	Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 821-834	4	3
34	Prevalence of post-prostatectomy erectile dysfunction and a review of the recommended therapeutic modalities. <i>International Journal of Impotence Research</i> , 2021 , 33, 401-409	2.3	9
33	Comparison of efficacy and safety of daily oral L-arginine and PDE5Is alone or combination in treating erectile dysfunction: A systematic review and meta-analysis of randomised controlled trials. <i>Andrologia</i> , 2021 , 53, e14007	2.4	2
32	Pathophysiology and Grayscale Ultrasonography of Penile Corporal Fibrosis. <i>Sexual Medicine Reviews</i> , 2021 , 10, 99-99	5.6	
31	Evaluation of Retinal and Choroidal Microcirculation Alterations After a Single Dose of Oral 5-mg Tadalafil: A Prospective Pilot Optical Coherence Tomography Angiography Study. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021 , 37, 421-429	2.6	
30	European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. <i>European Urology</i> , 2021 , 80, 333-357	10.2	64
29	Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. <i>International Journal of Impotence Research</i> , 2021 ,	2.3	2
28	Role of identified noncoding RNA in erectile dysfunction. <i>Andrologia</i> , 2020 , 52, e13596	2.4	4
27	The treatment of erectile dysfunction in patients with neurogenic disease. <i>Translational Andrology and Urology</i> , 2016 , 5, 88-101	2.3	19
26	An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy. <i>Asian Journal of Andrology</i> , 2015 , 17, 61-7	2.8	12
25	A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. <i>Asian Journal of Andrology</i> , 2017 , 19, 500-504	2.8	5
24	Role of Phosphodiesterase Type 5 Inhibitor on Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms. <i>Korean Journal of Andrology</i> , 2011 , 29, 91		1
23	Urologic/Clinical Treatment of Erectile Dysfunction. 2016 , 53-63		

22 Sexualität und Psychiatrie. **2018**, 285-295

21 La medicalizzazione della sessualità maschile. *Rivista Di Sessuologia Clinica*, **2018**, 5-35

0

20 Safety and Efficacy of Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction: A Systematic Review and Meta-Analysis. **2019**, 2,

19 Erectile dysfunction: drug treatment. *Revista Da Associação Médica Brasileira*, **2019**, 65, 1133-1142

1.4

1

18 Rehabilitation in der Uroonkologie: Erektile Dysfunktion. *Springer Reference Medizin*, **2020**, 1-9

0

17 Pharmacological management of male sexual dysfunction. *Journal of the Korean Medical Association*, **2020**, 63, 356-364

0.5

16 Sexual dysfunction. **2020**, 2408-2415

15 Pharmacology of Male Sexual Function. **2020**, 159-174

14 Efficacy and Safety of Oral Combination of Yohimbine and L-arginine (SX) for the Treatment of Erectile Dysfunction: a multicenter, randomized, double blind, placebo-controlled clinical trial. *Iranian Journal of Psychiatry*, **2010**, 5, 1-3

1.9

7

13 Advances Towards the Synthesis of Aporphine Alkaloids: C-Ring Formation via Approaches Based on One- and Two-Bond Disconnections. *Chemical Record*, **2021**,

6.6

1

12 Management strategies of sexual dysfunctions in Parkinson's disease.. *International Review of Neurobiology*, **2022**, 162, 97-116

4.4

11 A Review on Phosphodiesterase-5 Inhibitors as a Topical Therapy for Erectile Dysfunction.. *Sexual Medicine Reviews*, **2022**,

5.6

1

10 Data_Sheet_1.doc. **2018**,

9 Image_1.PDF. **2018**,

8 Image_2.PDF. **2018**,

7 Restorative medicine in the aging genitourinary system. **2023**, 347-357

0

6 Majority of erectile dysfunction patients would have preferred earlier implantation of their penile prosthesis: validation of the recently changed EAU guidelines.

0

5 Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review. **2022**, 10, 764-781

0

- 4 Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction. ○
- 3 Value of transrectal color Doppler ultrasound of the common penile arteries in the diagnosis of arteriogenic erectile dysfunction: A pilot study. 039156032311623 ○
- 2 Papaverine: A Miraculous Alkaloid from Opium and Its Multimedicinal Application. **2023**, 28, 3149 ○
- 1 Current trends in pharmacotherapy of erectile dysfunction. **2023**, 37, 5-9 ○